Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Shiffman, Dov ^a   Trompet, Stella ^b   Louie, Judy Z ^a   Rowland, Charles M ^a   Catanese, Joseph J ^a   Iakoubova, Olga A ^a   Kirchgessner, Todd G ^c   Westendorp, Rudi G J ^b   de Craen, Anton J M ^b   Slagboom, P Eline ^b   Buckley, Brendan M ^d   Stott, David J ^e   Sattar, Naveed ^f   Devlin, James J ^a   Packard, Christopher J ^e   Ford, Ian ^e   Sacks, Frank M ^g   Jukema, J Wouter ^b,h,i  

^a CELERA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h Durrer Center for Cardiogenetic Research   (Netherlands)

ⁱ ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; PROTEIN DNAJ;

ARTICLE; DNAJC5B GENE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; CORONARY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRAVASTATIN;

EID: 84861695039     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038240     Document Type: Article

References (29)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366, 1267-1278.
2. Maitland-van der Zee AH, Boerwinkle E, (2005) Pharmacogenetics of response to statins: where do we stand? Curr. Atheroscler. Rep,.7, 204-208.
3. Mangravite LM, Thorn CF, Krauss RM, (2006) Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J., 6, 360-374.
4. Voora D, Ginsburg GS, Pharmacogenetics of the response to statins, (2009) Current Cardiovascular Risk Reports. 3, 434-440.
5. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, et al. (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 291, 2821-2827.
6. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, et al. (2005) An association study of 43 SNPs in 16 candidate genes with atorvastatin response. The Pharmacogenomics J., 5, 352-358.
7. Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR, et al. (2008) Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ. Cardiovasc. Genet., 1, 100-106.
8. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, et al. (2008) Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 117, 1537-1544.
9. Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, (2009) Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort. Circ. Cardiovasc. Genet., 2, 173-181.
10. Iakoubova OA, Tong CH, Rowland CM, Kirchgessner TG, Young BA, et al. (2008) Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol., 51, 435-443.
11. Iakoubova OA, Robertson M, Tong CH, Rowland CM, Catanese JJ, et al. (2010) KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Eur. J. Cardiovasc. Prev. Rehabil., 17, 455-461.
12. Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, et al. (2008) Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol., 51, 449-455.
13. Hopewell JC, Parish S, Clarke R, Armitage J, Bowman L, et al. (2011) No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J. Am. Coll. Cardiol., 57, 2000-2007.
14. Ridker PM, Macfadyen JG, Glynn RJ, Chasman DI, (2011) Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary Prevention. Circ. Cardiovasc. Genet., 4, 312-317.
15. Davis BR, Ford CE, Boerwinkle, E, Arnett D, Eckfeldt J, et al. (2004) Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses-a new method for the Genetics of Hypertension Associated Treatment (GenHAT) study. Statist. Med.; 23, 2413-2427.
16. Qiu XB, Shao YM, Miao S, Wang L, (2006) The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell. Mol. Life. Sci., 63, 2560-2570.
17. Evans GJ, Morgan A, Burgoyne RD, (2003) Tying everything together: the multiple roles of cysteine string protein (CSP) in regulated exocytosis. Traffic. 4, 653-659.
18. Gorleku OA, Chamberlain LH, (2010) Palmitoylation and testis-enriched expression of the cysteine-string protein beta isoform. Biochemistry. 49, 5308-5313.
19. Johnson JN, Ahrendt E, Braun JEA, (2010) CSPalpha: the neuroprotective J protein. Cell 165, 157-165.
20. Wang CY, Liu PY, Liao JK, (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med., 14: 37-44.
21. Ference BA, Yoo W, Flack JM, Clarke M, (2012) A common KIF6 polymorphism increases vulnerability to low-density lipoprotein cholesterol: two meta-analyses and a meta-regression analysis. PLoS One. 6: e28834.
22. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001-1009.
23. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 16, 333: 1301-1307.
24. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 360, 1623-1630.
25. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, et al. (2010) ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 464, 405-408.
26. Shiffman, D, Ellis SG, Rowland CM, Malloy MJ, Luke MM, et al. (2005) Identification of four gene variants associated with myocardial infarction. Am. J. Hum. Genet., 77, 596-605.
27. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet., 81, 559-575.
28. Shiffman D, Sabatine MS, Louie JZ, Kirchgessner TG, Iakoubova OA, et al. (2010) Effect of Pravastatin Therapy on Coronary Events in Carriers of the KIF6 719Arg Allele from the Cholesterol and Recurrent Events Trial. Amer J Cardiol., 105, 1300-1305.
29. R Development Core Team (2011) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/.